IT IS WELL ESTABLISHED that ␤-adrenoceptor activation stimulates adenylyl cyclase activity through the participation of G proteins and promotes the formation of cAMP in the myocardium (1, 3, 10, 38) . The elevated level of cAMP increases the intracellular concentration of Ca 2ϩ ([Ca 2ϩ ] i ) in cardiomyocytes on protein kinase A-mediated phosphorylation of different Ca 2ϩ -handling proteins in the membrane and produces the positive inotropic effect in the heart (1, 3, 10, 38) . This ␤-adrenoceptor-mediated signal transduction mechanism not only regulates the contractile activity of the healthy heart, but it is also considered to provide critical support for the maintenance of cardiac function during the development of heart failure (1, 3, 10, 28) . Although varying degrees of defects in the ␤-adrenoceptor-mediated signal transduction mechanisms have been observed in the failing heart at terminal stages (2, 4, 17, 28, 39) , it has been reported that these events in different types of heart failure are unaltered, upregulated, or downregulated (19, 31-33, 43, 44) . Since cardiac hypertrophy is invariably associated with heart failure (16, 45) , it is possible that the conflicting results regarding changes in ␤-adrenoceptor-mediated mechanisms during the development of heart failure are due to differences in the type and stage of hypertrophied failing hearts. Accordingly, this study was undertaken to test whether alterations in ␤-adrenoceptor signal transduction in cardiac hypertrophy due to pressure overload (PO) are different from those due to volume overload (VO). PO is known to induce the concentric form of cardiac hypertrophy (6, 8, 25) , whereas VO has been shown to produce the eccentric form of cardiac hypertrophy (6, 8, 42 ).
METHODS

Experimental model and hemodynamic assessment. All protocols for experiments were approved by the University of Manitoba Animal
Care Committee in accordance with the guidelines of the Canadian Council on Animal Care. Male Sprague-Dawley rats weighing 175-200 g each were used in the study. Cardiac hypertrophy due to PO was induced by 4 and 24 wk of abdominal aorta occlusion, as described earlier (6) . Cardiac hypertrophy due to VO was induced by creation of an aortocaval shunt for 4 and 24 wk, as described previously (6, 42) . The selection of 4-and 24-wk periods for PO and VO is based on our experience with these experimental models for the induction of early (compensated) and late (decompensated) stages of cardiac hypertrophy, respectively. Sham-operated rats for each group were used as controls. In one set of experiments, 12 animals for each PO or VO group were anesthetized with an intraperitoneal injection of a mixture of ketamine (90 mg/kg) and xylazine (10 mg/kg). These animals were assessed hemodynamically with a microtipped pressure transducer (model SPR-249, Millar Instruments, Houston, TX). Left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), rate of change of pressure development (ϩdP/dt), and rate of change of pressure decay (ϪdP/dt) were recorded. Left ventricular developed pressure (LVDP) was calculated as LVSP Ϫ LVEDP. The heart, lung, and liver weights, ␤-adrenoceptor binding parameters, adenylyl cyclase activity, and effect of isoproterenol on [Ca 2ϩ ]i in cardiomyocytes isolated from these hearts were determined. The second set of experiments was carried out on four animals in each PO or VO group to investigate the isoproterenol-mediated changes in LVDP.
Isoproterenol-induced changes in cardiac function. To assess the effect of isoproterenol on cardiac function under controlled conditions, hearts from PO and VO, as well as sham, animals were isolated and perfused with oxygenated Krebs-Henseleit solution containing 1.25 mM Ca 2ϩ at 37°C according to the technique used previously (42, 44) . The hearts were paced electrically at 300 beats/min, and the coronary flow was maintained at 10 ml/min. Isoproterenol (1 M) was infused into the perfusion stream, and the positive inotropic effect was measured at the peak point.
Determination of ␤-adrenoceptor binding characteristics and adenylyl cyclase activity. Crude membrane fraction, isolated from the left ventricle (43, 44) (43) . The reaction mixture contained 10 M GTP and 0.3% ascorbic acid for study of the adenylyl cyclase activity in the absence and presence of isoproterenol (100 M).
Measurement of [Ca 2ϩ ]i in cardiomyocytes. Purified cardiomyocytes were isolated from the left ventricle according to the procedure described earlier (30) . The cardiomyocytes were loaded with fura 2-AM, washed, and incubated with and without isoproterenol (100 M) for 5 min. [Ca 2ϩ ]i was measured in the absence and presence of 30 mM KCl, a known depolarizing agent, using spectrofluorometry, as described previously (30) . The KCl-induced increase in [Ca 2ϩ ]i was calculated as the net increase above the basal value, whereas the isoproterenol-induced increase in [Ca 2ϩ ]i was calculated by subtraction of KCl-induced values in the absence of isoproterenol from those in the presence of isoproterenol.
Statistical analysis. Values are means Ϯ SE. The difference between control and experimental groups was evaluated statistically by one-way ANOVA followed by the Newman-Keuls test. Differences were considered significant at P Ͻ 0.05.
RESULTS
General characteristics and hemodynamic changes.
The data in Table 1 describe the general characteristics of animals subjected to 4 and 24 wk of PO or VO. Heart weight and heart weight-to-body weight ratio at 4 and 24 wk of PO or VO were significantly increased compared with the respective values of the sham control animals. Increases in these parameters indicated a higher degree of cardiac hypertrophy in VO than in PO animals.
No change in lung weight or liver enlargement was seen in PO animals. VO animals showed an increase in lung weight and no changes in liver weight at 4 wk but an increase in lung and liver weights at 24 wk (Table 1) . In contrast to 4 and 24 wk of PO and 4 wk of VO, breathing difficulty and sluggish movement, in addition to the clinical signs of congestive heart failure, such as edema and pleural effusion, were noted at 24 wk of VO.
PO and VO animals were assessed hemodynamically, and the results are given in Figs. 1 and 2, respectively. At 4 wk of PO, LVDP, LVEDP, ϩdP/dt, and ϪdP/dt were significantly increased by 10 Ϯ 3.9%, 241 Ϯ 7.9%, 28 Ϯ 5.8%, and 25 Ϯ 5.2%, respectively; at 24 wk of PO, LVDP, ϩdP/dt, and ϪdP/dt were depressed by 43 Ϯ 3.9%, 28 Ϯ 5.3%, and 31 Ϯ 5.7%, respectively, but LVEDP was elevated (291 Ϯ 2.4%; Fig. 1 ). At 4 wk of VO, no changes in LVDP, ϩdP/dt, and ϪdP/dt were apparent, whereas LVEDP was significantly increased (276 Ϯ 12.8%; Fig. 2 ). At 24 wk of VO, a marked increase in LVEDP (365 Ϯ 10.2%) was associated with a significant decrease in LVDP, ϩdP/dt, and ϪdP/dt: 50 Ϯ 4.9%, 31 Ϯ 2.8%, and 39 Ϯ 2.3%, respectively (Fig. 2) .
Positive inotropic effect of isoproterenol. Changes in the inotropic effect of isoproterenol were examined by infusion of isoproterenol into the perfusion stream; the results (i.e., its peak action on LVDP) are given in Fig. 3 . Isoproterenol produced positive inotropic action in sham control, as well as PO and VO, hearts. However, at 4 wk of PO, the magnitude of the positive inotropic effect of isoproterenol was not different from the control (122 Ϯ 10.2% and 106 Ϯ 8.3%, respectively) but was markedly attenuated at 24 wk (100 Ϯ 5.10% and 56 Ϯ 3.7%, respectively; Fig. 3 ). The positive inotropic action of isoproterenol was augmented at 4 wk (260 Ϯ 12.9% vs. 103 Ϯ 7.2%) but markedly depressed at 24 wk (38 Ϯ 2.7% vs. 89 Ϯ 6.8%) of VO (Fig. 3) . In contrast to 4 wk of PO or VO, at 24 wk of PO or VO, LVDP in the isolated heart preparations was significantly depressed (Fig.  3) . Since the increase in LVDP from hearts at 4 wk of PO was not evident in the isolated preparations, in contrast to in vivo conditions, the differences between in vivo and in vitro preparations at this stage of cardiac hypertrophy may be due to washout of different humoral and growth factors circulating in the body on perfusion of the isolated hearts. Further studies in which these factors are inhibited and their in vivo and in vitro effects are compared are needed to understand such differences.
Changes in ␤-adrenoceptors and adenylyl cyclase. The data in Table 2 show that PO induced no change in B max or affinity (1/K d ) for ␤ 1 -adrenoceptors at 4 wk, whereas B max was decreased without any change in the affinity at 24 wk. VO induced a marked increase in B max at 4 wk and a decrease at 24 wk, with no change in the affinity of ␤ 1 -adrenoceptors (Table  2) . Although isoproterenol increased adenylyl cyclase activity at 4 and 24 wk in sham control and PO animals, the activation of adenylyl cyclase by isoproterenol was unaltered at 4 wk but depressed at 24 wk of PO (Table 3 ). The adenylyl cyclase activity in the absence of isoproterenol at 24 wk of PO was also less than the respective control value. Furthermore, the activation of adenylyl cyclase by isoproterenol was augmented at 4 wk and depressed at 24 wk of VO (Table 3 ). The adenylyl cyclase activity in the absence of isoproterenol at 4 and 24 wk of VO was not different from the respective control value.
Isoproterenol-induced changes in [Ca 2ϩ ] i in cardiomyocytes. Alterations in [Ca 2ϩ ] i in the absence and presence of isoproterenol were studied in quiescent and KCl-depolarized cardiomyocytes at 4 and 24 wk of PO and VO, and the results are shown in Figs. 4 (Fig. 4) . On the other hand, the isoproterenol-mediated increase in [Ca 2ϩ ] i was augmented by 51 Ϯ 2.8% at 4 wk of VO and depressed by 128 Ϯ 9.8% at 24 wk of VO (Fig. 5) .
DISCUSSION
In this study, we have shown that cardiac hypertrophy, as reflected by increased heart weight and heart weight-to-body weight ratio, was associated with an increase in cardiac function, as reflected by increased LVDP, ϩdP/dt, and ϪdP/dt, at 4 wk of PO. On the other hand, cardiac hypertrophy at 4 wk of VO was associated with unaltered cardiac function. Since LVEDP was increased at 4 wk of PO and VO, it is likely that the development of cardiac hypertrophy at this early stage of PO and VO may be a consequence of increased ventricular wall tension. This view is supported by the association of increased heart weight with the greater increase in LVEDP at 24 wk than at 4 wk of PO or VO. Also, no changes in lung weight or liver weight were observed at 4 and 24 wk of PO, whereas lung weight was increased at 4 and 24 wk of VO and liver weight was increased at 24 wk of VO. In addition, clinical signs of congestive heart failure induced by PO are different from those at 24 wk of VO. These differences between PO and VO animals are in agreement with numerous reports showing varying degrees of alterations in general characteristics and heart function in these experimental models of cardiac remodeling (9, 12, 14, 20, 24) . Such differences in cardiac function at the early stages of cardiac hypertrophy may be due to the development of concentric and eccentric types of cardiac hypertrophy in PO and VO animals, respectively (6 -8, 22, 27) . Although changes in shape and size of cardiomyocytes (cardiac remodeling) are considered to represent a major mechanism of cardiac dysfunction (5, 21), cardiac hypertrophy has been reported to be associated with unaltered, enhanced, or depressed heart function (8, 14, 16, 45) . Such findings are consistent with our observations that cardiac function was depressed in hypertrophied hearts at 24 wk of PO or VO, unaltered in hypertrophied hearts at 4 wk of VO, and augmented in hypertrophied hearts at 4 wk of PO. The development of cardiac hypertrophy is an adaptive phenomenon to maintain cardiac function during early stages but may result in cardiac dysfunction at late stages of stress on the heart (5, 14, 16, 21) .
In view of the activation of the sympathetic nervous and renin-angiotensin systems, as well as increased formation of growth factors on induction of PO and VO (11, 15, 16, 22, 29) , it appears that compensated and decompensated forms of cardiac hypertrophy may depend on the duration of exposure of the heart to different humoral and other growth factors circulating in the body. For the purpose of comparison, we believe that animals subjected to 4 and 24 wk of PO or VO are at compensated and decompensated stages of cardiac hypertrophy, respectively; however, there are marked differences between the PO and VO models of cardiac hypertrophy with respect to cardiac function. Preliminary experiments in our laboratory have indicated that cardiac function in hypertrophied hearts due to PO begins to decline at ϳ6 wk, whereas no clinical signs of congestive heart failure were evident at 48 wk of PO in rats. On the other hand, in rat hearts in which hypertrophy was induced by VO, cardiac function declined at 10 wk, and clinical signs of congestive heart failure become apparent at 12 wk. Thus extensive studies over different periods of PO-or VO-induced cardiac hypertrophy are needed to understand the molecular and cellular basis of cardiac dysfunction.
The results presented in this study indicate that ␤-adrenoceptor-mediated signal transduction mechanisms are unaltered or upregulated in the compensated stages of cardiac hypertrophy and are downregulated in the decompensated stages of cardiac hypertrophy. This view is based on our observations that the positive inotropic effect of isoproterenol, ␤ 1 -adrenoceptor density, stimulation of adenylyl cyclase activity by isoproterenol, and isoproterenol-induced increase in [Ca 2ϩ ] i were unaltered at 4 wk of PO but were augmented at 4 wk of VO. Furthermore, the number of ␤ 1 -adrenoceptors, as well as the increase in contractile activity of the heart, stimulation of adenylyl cyclase activity, and increase in [Ca 2ϩ ] i in cardiomyocytes mediated by isoproterenol, were attenuated at 24 wk of PO or VO. Earlier studies showed an increase in ␤ 1 -adrenoceptor density, as well as an augmentation of the isoproterenolinduced increase in adenylyl cyclase activity and contractile force development, at 16 wk of VO in rats (43, 44) . A PO-induced increase in ␤-adrenoceptor density at early stages of cardiac hypertrophy has also been reported in rats and guinea pigs (15, 18) . On the other hand, depression of the density of ␤ 1 -adrenoceptors, as well as an isoproterenol-induced increase in cardiac contraction and stimulation of adenylyl cyclase activity, has been observed in dogs with POinduced congestive heart failure (13, 40, 41) . Thus it appears that the time course for the development of cardiac dysfunction, as well as occurrence of changes in ␤-adrenoceptor signal transduction mechanisms, in PO-induced cardiac hypertrophy is different from that in VO-induced cardiac hypertrophy.
A detailed investigation employing cardiomyopathic hamsters at different stages of heart failure has indicated that ␤ 1 -adrenoceptor density and isoproterenol-induced stimulation of adenylyl cyclase activity were increased at early stages and decreased at late stages of congestive heart failure (19, 31, 34) . Since varying degrees of cardiac hypertrophy were evident in all studies indicated above, it appears that alterations in ␤-adrenoceptor signal transduction are dependent on the type and stage of the cardiac hypertrophy in different experimental models of heart failure. Furthermore, upregulation of ␤-adrenoceptor mechanisms in compensated cardiac hypertrophy may play an adaptive role in maintaining heart function, whereas downregulation of this mechanism in decompensated cardiac hypertrophy may reflect the loss of its support to the failing heart. Although this study has identified differential changes in various components of the ␤-adrenoceptor-mediated signal transduction system at compensated and decompensated stages of PO-and VO-induced cardiac hypertrophy, the mechanisms for such alterations remain to be investigated. Such studies may deal with gene and protein expression for different components of the ␤-adrenoceptor signal transduction, as well as for the regulatory mechanisms, including G protein-coupled receptor kinases, ␤-arrestins, and G␤␥ protein subunits. Since the renin-angiotensin and sympathetic nervous systems are activated on the induction of PO or VO, as well as during the development of congestive heart failure (11, 15, 16, 28, 29, 36, 37, 39) , it is possible that the activation of these systems at the local level in the heart may upregulate the ␤-adrenoceptor mechanisms during the compensated stages of cardiac hypertrophy, whereas their activation for prolonged periods may result in decompensated cardiac hypertrophy and downregulation of ␤-adrenoceptor mechanisms. Similar mechanisms can be invoked with respect to an increase in ventricular wall stress to explain the biphasic changes in ␤-adrenoceptor signal transduction during compensated and decompensated stages of cardiac hypertrophy, because PO or VO resulted in a progressive increase in the LVEDP. Since oxidative stress is increased during the development of heart failure (23) and oxidative stress has been shown to produce biphasic changes in the ␤-adrenoceptor signal transduction (26) , it is likely that the PO-or VO-induced differential alterations in ␤-adrenoceptor mechanisms may also be the consequence of increased oxidative stress. Similar mechanisms have also been suggested to explain changes in ␤-adrenoceptor signal transduction in left and right ventricles of infarcted animals (35) .
